Assembly and Interrogation of Alzheimer’s Disease Genetic Networks Reveal Novel Regulators of Progression

Alzheimer’s disease (AD) is a complex multifactorial disorder with poorly characterized pathogenesis. Our understanding of this disease would thus benefit from an approach that addresses this complexity by elucidating the regulatory networks that are dysregulated in the neural compartment of AD patients, across distinct brain regions. Here, we use a Systems Biology (SB) approach, which has been highly successful in the dissection of cancer related phenotypes, to reverse engineer the transcriptional regulation layer of human neuronal cells and interrogate it to infer candidate Master Regulators (MRs) responsible for disease progression. Analysis of gene expression profiles from laser-captured neurons from AD and controls subjects, using the Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNe), yielded an interactome consisting of 488,353 transcription-factor/target interactions. Interrogation of this interactome, using the Master Regulator INference algorithm (MARINa), identified an unbiased set of candidate MRs causally responsible for regulating the transcriptional signature of AD progression. Experimental assays in autopsy-derived human brain tissue showed that three of the top candidate MRs (YY1, p300 and ZMYM3) are indeed biochemically and histopathologically dysregulated in AD brains compared to controls. Our results additionally implicate p53 and loss of acetylation homeostasis in the neurodegenerative process. This study suggests that an integrative, SB approach can be applied to AD and other neurodegenerative diseases, and provide significant novel insight on the disease progression.

[1]  Andrea Califano,et al.  Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. , 2013, Cancer cell.

[2]  J. Pozueta,et al.  Synaptic changes in Alzheimer’s disease and its models , 2013, Neuroscience.

[3]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[4]  J. Pozueta,et al.  Cross-Linking of Cell Surface Amyloid Precursor Protein Leads to Increased β-Amyloid Peptide Production in Hippocampal Neurons: Implications for Alzheimer's Disease , 2012, The Journal of Neuroscience.

[5]  A. Butte,et al.  Leveraging models of cell regulation and GWAS data in integrative network-based association studies , 2012, Nature Genetics.

[6]  Andrea Califano,et al.  Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL , 2011, Nature Medicine.

[7]  Dong-Sun Han,et al.  Acetylation of the Pro-Apoptotic Factor, p53 in the Hippocampus following Cerebral Ischemia and Modulation by Estrogen , 2011, PloS one.

[8]  Menno P. Witter,et al.  A pathophysiological framework of hippocampal dysfunction in ageing and disease , 2011, Nature Reviews Neuroscience.

[9]  W. Gu,et al.  The impact of acetylation and deacetylation on the p53 pathway , 2011, Protein & Cell.

[10]  S. Feinstein,et al.  Amyloid β-Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation* , 2011, The Journal of Biological Chemistry.

[11]  J. Trojanowski,et al.  The acetylation of tau inhibits its function and promotes pathological tau aggregation. , 2011, Nature communications.

[12]  N. Sharma,et al.  Nucleosome eviction and activated transcription require p300 acetylation of histone H3 lysine 14 , 2010, Proceedings of the National Academy of Sciences.

[13]  T. Kundu,et al.  Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. , 2010, Biochimica et biophysica acta.

[14]  Mariano J. Alvarez,et al.  A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers , 2010, Molecular systems biology.

[15]  Winnie S. Liang,et al.  Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology , 2010, Neurobiology of Aging.

[16]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[17]  E. Yaksi,et al.  Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.

[18]  Christopher M. Overall,et al.  Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology , 2009, Trends in Neurosciences.

[19]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[20]  S. Weitzman,et al.  p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc , 2008, Oncogene.

[21]  P. Casaccia‐Bonnefil,et al.  The Yin and Yang of YY1 in the nervous system , 2008, Journal of neurochemistry.

[22]  Eric M Reiman,et al.  Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. , 2008, Physiological genomics.

[23]  Winnie S. Liang,et al.  Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons , 2008, Proceedings of the National Academy of Sciences.

[24]  D. Geschwind,et al.  A Systems Level Analysis of Transcriptional Changes in Alzheimer's Disease and Normal Aging , 2008, The Journal of Neuroscience.

[25]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[26]  J. Vonsattel,et al.  Twenty-first century brain banking. Processing brains for research: the Columbia University methods , 2007, Acta Neuropathologica.

[27]  Nathaniel D. Heintzman,et al.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome , 2007, Nature Genetics.

[28]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[29]  K. Nowak,et al.  The transcription factor Yin Yang 1 is an activator of BACE1 expression , 2006, Journal of neurochemistry.

[30]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[31]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Ching-Chow Chen,et al.  Akt Phosphorylation of p300 at Ser-1834 Is Essential for Its Histone Acetyltransferase and Transcriptional Activity , 2005, Molecular and Cellular Biology.

[34]  R. Kraft,et al.  Caspase-Dependent Regulation and Subcellular Redistribution of the Transcriptional Modulator YY1 during Apoptosis , 2005, Molecular and Cellular Biology.

[35]  Adam A. Margolin,et al.  Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.

[36]  S. Kyrylenko,et al.  Changes in DNA binding pattern of transcription factor YY1 in neuronal degeneration , 2005, Neuroscience Letters.

[37]  P. Keller,et al.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.

[38]  J. Ericsson,et al.  YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[40]  S. Grossman,et al.  Yin Yang 1 Is a Negative Regulator of p53 , 2004, Cell.

[41]  O. Vitolo,et al.  Dendrite and dendritic spine alterations in alzheimer models , 2004, Journal of neurocytology.

[42]  M. Ball,et al.  Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia , 1977, Acta Neuropathologica.

[43]  Wei Gu,et al.  Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. , 2003, Current opinion in cell biology.

[44]  Richard Mohs,et al.  Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. , 2003, Archives of neurology.

[45]  R. Shiekhattar,et al.  A Candidate X-linked Mental Retardation Gene Is a Component of a New Family of Histone Deacetylase-containing Complexes* , 2003, The Journal of Biological Chemistry.

[46]  M. Ball,et al.  Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.

[47]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[48]  J M Lee,et al.  A gene expression profile of Alzheimer's disease. , 2001, DNA and cell biology.

[49]  Ya-Li Yao,et al.  Regulation of Transcription Factor YY1 by Acetylation and Deacetylation , 2001, Molecular and Cellular Biology.

[50]  N. L. La Thangue,et al.  p300/CBP proteins: HATs for transcriptional bridges and scaffolds. , 2001, Journal of cell science.

[51]  R. Goodman,et al.  CREB-binding Protein and p300 in Transcriptional Regulation* , 2001, The Journal of Biological Chemistry.

[52]  Ettore Appella,et al.  p300/CBP‐mediated p53 acetylation is commonly induced by p53‐activating agents and inhibited by MDM2 , 2001, The EMBO journal.

[53]  R. Hay,et al.  Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation , 2000, Molecular and Cellular Biology.

[54]  H. Ropers,et al.  DXS6673E encodes a predominantly nuclear protein, and its mouse ortholog DXHXS6673E is alternatively spliced in a developmental- and tissue-specific manner. , 2000, Genomics.

[55]  D. Holtzman,et al.  In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[56]  E. Seto,et al.  Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? , 1999, Gene.

[57]  Christina A. Wilson,et al.  Intracellular APP Processing and Aβ Production in Alzheimer Disease , 1999 .

[58]  S. Shimohama,et al.  Changes in caspase expression in Alzheimer's disease: comparison with development and aging. , 1999, Biochemical and biophysical research communications.

[59]  R. Doms,et al.  Intracellular APP processing and A beta production in Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[60]  K. Sakaguchi,et al.  DNA damage activates p53 through a phosphorylation-acetylation cascade. , 1998, Genes & development.

[61]  J. Wands,et al.  Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease , 1997, Journal of the Neurological Sciences.

[62]  J. Kere,et al.  Cloning and characterization of DXS6673E, a candidate gene for X-linked mental retardation in Xq13.1. , 1996, Human molecular genetics.

[63]  K. Becker,et al.  Characterization of hUCRBP (YY1, NF-E1, delta): a transcription factor that binds the regulatory regions of many viral and cellular genes. , 1994, Gene.

[64]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[65]  A. Nappi,et al.  Alzheimer ' s Disease : Cell-Specific Pathology Isolates the Hippocampal Formation , 2022 .